Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epoetin alfa in anemic CLL patients
NCT00270049Phase 2Completed
- Sponsor
- Johnson & Johnson
- Start
- Nov 1990
- Modality
- Biologic, rProtein (Recombinant Protein)
01
Overview
Phase 2, randomised, double-blind trial in anemia comparing Epoetin alfa with Placebo (2 arms). Primary endpoints: Percentage of patients who reach the target of 38% to 40% red blood cells at 12 weeks and Incidence of adverse events at 12 weeks. Started Nov 1990; status: completed.
02
Drugs
epoetin alfa
03
Conditions
anemia
Beyond the preview
Go deeper on NCT00270049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00270049.